The number of holders of debt instrument.

No definition available.

Name:	nnvc_NumberOfHoldersOfDebtInstrument
Namespace Prefix:	nnvc_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of direct costs.

+ References

No definition available.

+ Details

Name:	nnvc_PercentageOfDirectCosts
Namespace Prefix:	nnvc_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty expense calculated as a percentage of net sales.

+ References

No definition available.

+ Details

Name:	nnvc_PercentageOfNetSalesAllocatedForRoyaltyPayments
Namespace Prefix:	nnvc_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of the cost of borrowed funds accounted for as interest expense for debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

+ Details

Name:	us-gaap_InterestExpenseDebt
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of general and administrative expense classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

+ Details

Name:	us-gaap_OtherGeneralAndAdministrativeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	dei_LegalEntityAxis=nnvc_TheracourPharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=nnvc_SeriesCConvertibleDebentureMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnvc_DrBoniukMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=nnvc_SeriesBDebenturesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Related Party Transactions - Additional Information (Details)		12 Months Ended
	Oct. 02, 2018 USD ($)	Jun. 30, 2019 USD ($) item	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)
Related Party Transaction [Line Items]
Other General and Administrative Expense		$ 2,000
Percentage of Direct Costs		30.00%
Interest Expense, Debt		$ 0	$ 185,274	$ 780,767
Percentage Of Net Sales Allocated For Royalty Payments		15.00%
Research and Development Expense		$ 5,921,720	5,913,720	6,565,966
TheraCour Pharma, Inc [Member]
Related Party Transaction [Line Items]
Research and Development Expense	$ 25,000	3,119,863	3,176,977	3,368,919
Series C Convertible Debenture [Member]
Related Party Transaction [Line Items]
Interest Expense, Debt		5,000,000
Series C Convertible Debenture [Member] \| Dr. Boniuk [Member]
Related Party Transaction [Line Items]
Interest Expense, Debt		0	185,274	500,000
Series B Debentures [Member] \| Dr. Boniuk [Member]
Related Party Transaction [Line Items]
Interest Expense, Debt		$ 0	$ 0	$ 187,178
Number of Holders of Debt Instrument \| item		2